MAY 18, 2017 2:22 PM PDT

Treating A Rare Immunological Disease with Mepolizumab

WRITTEN BY: Kara Marker

There's a new standard treatment for a rare immunological disease: mepolizumab. No need for an approval process, though - the drug is already approved by the U.S. Food and Drug Administration (FDA) to treat another disease.

Micrograph showing high power view of Eosinophils. Credit: Department of Pathology, Calicut Medical College

The identification of a new treatment is promising news for people with the rare disease, called eosinophilic granulomatosis with polyangiitis (EGPA). Previously known as Churg-Strauss Syndrome, EGPA is characterized by excessive proliferation of eosinophils, a type of proinflammatory white blood cell involved in multiple immune processes, including allergic reactions. As the eosinophil population grows, cells start to collect in the blood vessel walls, meanwhile releasing toxic, inflammatory proteins that damage tissues around them.

An individual developing EGPA will first experience only severe asthma, but as time goes by, more blood flow is restricted, and more tissues are damaged, multi-organ damage will occur. Prior to mepolizumab, the only standard treatments for EGPA were oral steroids, taken regularly, and occasionally immunosuppressants. However, both options are accompanied by adverse side effects, relapses are common, and treatment doesn’t always work for some EGPA patients.

Mepolizumab was originally approved by the FDA to treat serious cases of eosinophilic asthma; the drug is a humanized monoclonal antibody of immunoglobulin G, and it targets an immune chemical called interleukin-5 to treat asthma.

The new phase 3 Clinical Trial, from the National Institute of Allergy and Infectious Diseases, examined the improvements made in patients when mepolizumab is added to steroid treatments for EGPA. Researchers conducted a double-blind experiment of 136 EGPA participants, where half of the study’s participants received mepolizumab and half received a placebo. All of the study’s participants either did not respond at all to steroids or relapsed after taking oral steroids.

Regardless of whether or not they also took immunosuppressants, nearly one-third of people receiving mepolizumab remained in remission for at least 24 weeks, but only three percent of the placebo participants remained in remission for that long.

The next step for getting mepolizumab into the hands of people struggling with EGPA: What biological markers can distinguish between people who would benefit from mepolizumab and those who would not?

The present study was published in the New England Journal of Medicine.

Sources: NIH/National Institute of Allergy and Infectious Diseases, Expert Review of Clinical Immunology, Cincinnati Center for Eosinophilic Disorders

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 11, 2019
Cardiology
SEP 11, 2019
Better Sleep, Brought To You By Exercise
Regular difficulty falling or staying asleep, called chronic insomnia, is the most common sleep disorder among adults. In the search for better, more restf...
OCT 23, 2019
Immunology
OCT 23, 2019
Treating Celiac Disease May Be Possible
Delivering gluten to the body in a friendly, harmless package may be the way for people with celiac disease to finally have a sandwich again. A new clinica...
OCT 25, 2019
Drug Discovery & Development
OCT 25, 2019
Novel Therapeutic For Eradicating The Flu Virus
Public Health officials have long warned about pandemic pathogens flying fast around the world. One virus already spreads across the globe annually leading...
NOV 03, 2019
Genetics & Genomics
NOV 03, 2019
Can CRISPR Replace Antibiotics?
Antibiotic-resistant infections claim around 700,000 lives per year, with estimates saying that this number could swell to 10 million by 2050 (Jacobs: 2019...
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
Potential Cure for Coronavirus Found in Thailand
Doctors in Thailand have successfully treated people affected by the coronavirus via a new drug cocktail made out of antiviral, flu and HIV medication. Alt...
FEB 17, 2020
Immunology
FEB 17, 2020
Another HIV vaccine attempt fizzles out
Years of work and over $100 million in study costs have been abandoned after an HIV-vaccine tested in South Africa failed to protect treated individuals ag...
Loading Comments...